Shares of FibroGen are soaring more than 50 percent in pre-market trading Tuesday after the biotech reported positive study results for a potential blockbuster drug. The biotech company's drug pamrevlumab, a treatment for fatal lung disease idiopathic pulmonary fibrosis, successfully completed a mid-stage FDA test. "Significant value creation should...